SCHEDULE 13D/A 0001437749-24-027668 0001015823 XXXXXXXX LIVE 9 Common Stock, $0.001 par value 12/18/2024 false 0001742927 76152G100 REVIVA PHARMACEUTICALS HOLDINGS, INC.

Vedanta Management, L.P. 250 West 55th Street, Ste 13D New York NY 10019

Parag Saxena 212-710-5220 Vedanta Management, L.P. 250 West 55th Street, Ste 13D New York NY 10019 0001865703 N Vedanta Associates-R, LP WC N DE 0.00 1967768.00 0.00 1967768.00 1967768.00 N 4.1 PN See Item 5 for additional information. 0001502222 N Vedanta Associates, L.P. AF WC N DE 0.00 3408401.00 0.00 3408401.00 3408401.00 N 6.9 PN See Item 5 for additional information. 0001614642 N Beta Operators Fund, L.P. WC N DE 0.00 2138130.00 0.00 2138130.00 2138130.00 N 4.4 PN See Item 5 for additional information. 0001502216 N VEDANTA PARTNERS, LLC AF N DE 0.00 5376169.00 0.00 5376169.00 5376169.00 N 10.6 OO See Item 5 for additional information. 0001015823 N Parag Saxena AF WC N K7 892737.00 5376169.00 892737.00 5376169.00 6268906.00 N 12.4 IN See Item 5 for additional information. Common Stock, $0.001 par value REVIVA PHARMACEUTICALS HOLDINGS, INC. This Amendment No. 9 to Schedule 13D (this "Amendment No. 9") filed on behalf of Parag Saxena, Vedanta Partners, LLC ("Vedanta Partners"), Beta Operators Fund, L.P. ("Beta Operators"), Vedanta Associates, L.P. ("Vedanta Associates"), and Vedanta Associates-R, L.P. ("Vedanta Associates-R" and collectively, the "Reporting Persons") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on September 4, 2018, as amended and supplemented by Amendment No. 1, Amendment No. 2 and Amendment No. 3 on January 19, 2021, Amendment No. 4 on June 3, 2021, Amendment No. 5 on September 12, 2022, Amendment No. 6 on November 30, 2023, Amendment No. 7 on May 31, 2024 and Amendment No. 8 on August 23, 2024 (as amended, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 9 does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D. The information set forth in rows 11 and 13 of the cover pages to this Amendment No. 9 are incorporated by reference into this Item 5. The percentages set forth in row 13 of each cover page are based on 46,602,699 outstanding shares of common stock, par value $0.0001 per share ("Common Stock"), of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the "Issuer"), as of January 30, 2025, as reported directly by the Issuer to the Reporting Persons. The information set forth in rows 7 through 10 of the cover pages to this Amendment No. 9 is incorporated by reference. The 1,966,768 shares of Common Stock reported as beneficially owned on this Amendment No. 9 by Vedanta Associates-R consist of the following: (i) 931,000 shares of Common Stock held directly, (ii) 521,934 shares of Common Stock underlying warrants, and (iii) 513,834 shares of Common Stock underlying pre-funded warrants. As a result, Vedanta Associates-R is deemed to beneficially own 4.1% of the outstanding shares of Common Stock of the Issuer as of December 20, 2024 (the "Filing Date"). The securities beneficially owned by Vedanta Associates-R excludes 689,150 shares of Common Stock issuable upon the exercise of 918,867 warrants held by Vedanta Associates-R, which contain an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the other Reporting Persons) would beneficially own in excess of 4.99% of the shares of Common Stock outstanding immediately after giving effect to the issuance of the shares of Common Stock issuable upon exercise of the warrants (the "Blocker"). The 2,138,130 shares of Common Stock reported as beneficially owned on this Amendment No. 9 by Beta Operators consist of the following: (i) 399,000 shares of Common Stock held directly, (ii) 869,565 shares of Common Stock underlying warrants, and (iii) 869,565 shares of Common Stock underlying pre-funded warrants. As a result, Beta Operators is deemed to beneficially own 4.4% of the outstanding shares of Common Stock of the Issuer as of the Filing Date. The securities beneficially owned by Beta Operators excludes 299,250 shares of Common Stock issuable upon the exercise of 399,000 warrants held by Beta Operators, which are subject to the Blocker. The 3,408,401 shares of Common Stock reported as beneficially owned on this Amendment No. 9 by Vedanta Associates consist of the following: (i) 99,539 shares of Common Stock held directly, (ii) 399,000 shares of Common Stock held by Beta Operators, (iii) 869,565 shares of Common Stock underlying warrants held by Beta Operators, (iv) 585,366 shares of Common Stock underlying warrants held by Vedanta R2 Partners, LP ("Vedanta R2"), (v) 869,565 shares of Common Stock underlying pre-funded warrants held by Beta Operators, and (vi) 585,366 shares of Common Stock underlying pre-funded warrants held by Vedanta R2. As a result, Vedanta Associates is deemed to beneficially own 6.9% of the outstanding shares of Common Stock of the Issuer as of the Filing Date. The 5,375,169 shares of Common Stock reported as beneficially owned on this Amendment No. 9 by Vedanta Partners consist of the following: (i) 931,000 shares of Common Stock held by Vedanta Associates-R, (ii) 399,000 shares of Common Stock held by Beta Operators, (iii) 99,539 shares of Common Stock held by Vedanta Associates, (iv) 521,934 shares of Common Stock underlying warrants held by Vedanta Associates-R, (v) 869,565 shares of Common Stock underlying warrants held by Beta Operators, (vi) 585,366 shares of Common Stock underlying warrants held by Vedanta R2, (vii) 513,834 shares of Common Stock underlying pre-funded warrants held by Vedanta Associates-R, (vii) 869,565 shares of Common Stock underlying pre-funded warrants held by Beta Operators, and (viii) 585,366 shares of Common Stock underlying pre-funded warrants held by Vedanta R2. As a result, Vedanta Partners is deemed to beneficially own 10.6% of the outstanding shares of Common Stock of the Issuer as of the Filing Date. The 6,267,906 shares of Common Stock reported as beneficially owned on this Amendment No. 9 by Mr. Saxena consist of the following: (i) 871,337 shares of Common Stock held directly, (ii) 931,000 shares of Common Stock held by Vedanta Associates-R, (iii) 399,000 shares of Common Stock held by Beta Operators, (iv) 99,539 shares of Common Stock held by Vedanta Associates, (v) 521,934 shares of Common Stock underlying warrants held by Vedanta Associates-R, (vi) 869,565 shares of Common Stock underlying warrants held by Beta Operators, (vii) 585,366 shares of Common Stock underlying warrants held by Vedanta R2, (viii) 513,834 shares of Common Stock underlying pre-funded warrants held by Vedanta Associates-R, (vii) 869,565 shares of Common Stock underlying pre-funded warrants held by Beta Operators, (ix) 585,366 shares of Common Stock underlying pre-funded warrants held by Vedanta R2, and (x) 21,400 underlying options that are fully vested as of the Filing Date. As a result, Mr. Saxena is deemed to beneficially own 12.4% of the outstanding shares of Common Stock of the Issuer as of the Filing Date. The securities beneficially owned by Mr. Saxena exclude 8,200 shares underlying options that are unvested as of 60 days of the Filing Date. In accordance with Rule 13d-3, the beneficial ownership percentage for each Reporting Person assumes that the warrants and options that can be exercised within 60 days of the Filing Date, if any, held by such Reporting Person have been exercised, and that no other warrants or options have been exercised. The Reporting Persons have not effected any transactions during the past sixty (60) days from the date of this filing in any securities of the Issuer, other than the options to purchase 8,200 shares of the Issuer's Common Stock that were granted to Mr. Saxena on December 10, 2024 in connection with his service as a director of the Issuer. Except as otherwise reported herein, no person or entity other than the Reporting Persons have the right to receive, or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares of the Common Stock reported on this Schedule 13D. Each of Vedanta Associates-R and Beta Operators ceased to be a beneficial holder of more than five percent of the Issuer's Common Stock on December 18, 2024. Vedanta Associates-R, LP By: Vedanta Partners, LLC, the general partner ("GP") of Vedanta Associates-R, L.P. /s/ Parag Saxena 01/31/2025 Vedanta Associates, L.P. By: Vedanta Partners, LLC, the GP of Vedanta Associates, L.P. /s/ Parag Saxena 01/31/2025 Beta Operators Fund, L.P. By: Vedanta Associates, L.P., the GP of Beta Operators Fund, L.P. By: Vedanta Partners, LLC, the GP of Vedanta Associates, L.P. /s/ Parag Saxena 01/31/2025 VEDANTA PARTNERS, LLC /s/ Parag Saxena 01/31/2025 Parag Saxena /s/ Parag Saxena 01/31/2025